Short Interest in Synlogic, Inc. (NASDAQ:SYBX) Decreases By 38.5%

Synlogic, Inc. (NASDAQ:SYBX) saw a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 9,485 shares, a decline of 38.5% from the November 30th total of 15,427 shares. Based on an average trading volume of 98,523 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the company’s stock are sold short. Approximately 0.1% of the company’s stock are sold short. Based on an average trading volume of 98,523 shares, the short-interest ratio is presently 0.1 days.

Synlogic Stock Up 4.3%

Shares of SYBX opened at $1.22 on Monday. The business’s fifty day moving average is $1.46 and its 200 day moving average is $1.47. Synlogic has a 12-month low of $0.90 and a 12-month high of $1.96. The stock has a market cap of $14.27 million, a P/E ratio of -4.69 and a beta of 0.36.

Synlogic (NASDAQ:SYBX) last released its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.08). On average, analysts expect that Synlogic will post -2.71 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Synlogic in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Hedge Funds Weigh In On Synlogic

A hedge fund recently bought a new stake in Synlogic stock. Citadel Advisors LLC bought a new stake in shares of Synlogic, Inc. (NASDAQ:SYBX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 29,011 shares of the biotechnology company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned about 0.25% of Synlogic as of its most recent SEC filing. 63.40% of the stock is owned by institutional investors.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.